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Objectives: To evaluate the impact of preoperative atrial ﬁbrillation (pre-op AF) on early and late
mortality after isolated coronary artery bypass graft (CABG) surgery.
Methods: Data obtained prospectively between June 2001 and December 2009 by the Australasian
Society of Cardiac and Thoracic Surgeons National Cardiac Surgery Database Program were
retrospectively analyzed. Patients who underwent concomitant atrial arrhythmia surgery/ablation
were excluded. Demographic and operative data were compared between patients with and without
pre-op AF. The independent association of pre-op AF on early mortality, perioperative complications, and
late mortality was determined.
Results: Isolated CABG surgery was performed in 21,534 patients; 1312 (6.1%) presented with pre-op AF.
Pre-op AF patients were older (mean age, 71 years vs. 65 years, p < 0.001) and had more comorbidities
reﬂected in a higher additive EuroSCORE (8.4  3.5 vs. 6.5  3.2, p = 0.001). Even after accounting for
confounding factors, however, pre-op AF was associated with a 63% increase in 30-day mortality [4.2% vs.
1.4%; hazard ratio (HR), 1.63; 95% conﬁdence interval (CI), 1.17–2.29; p = 0.004] and 39% increase in late
mortality (5-year survival, 78% vs. 90%; HR, 1.39; 95% CI, 1.20–1.61; p < 0.001).
Conclusion: Pre-op AF is an independent predictor of poor early and late outcomes. Pre-op AF should be
considered, therefore, in the development or update of risk stratiﬁcation models for CABG surgery.
 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Atrial ﬁbrillation (AF) is the most common sustained arrhyth-
mia, with an estimated overall prevalence of 4% in the Australian
population aged greater than 30 years [1]. The incidence of AF is
reported to increase with age, with a prevalence as high as 15% in
those aged older than 80 years [1,2], as well as with other
cardiovascular comorbidities, such as valvular disease, ischemic* Corresponding author at: Department of Cardiothoracic Surgery, St Vincent’s
Hospital Melbourne, P.O. Box 2900, Fitzroy, Victoria 3065, Australia.
Tel.: +61 3 9288 3989; fax: +61 3 9417 1694.
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0914-5087/ 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardioloheart disease, and hypertension [3,4]. The average age of patients
requiring coronary artery bypass grafting (CABG) for ischemic
heart disease is increasing, and as a result, preoperative AF (pre-op
AF) is a common ﬁnding in surgical candidates. Data from several
large studies suggest that the prevalence of AF in patients
undergoing isolated CABG ranges from 5 to 22% [5–9].
While the adverse impacts of AF on general cardiovascular
morbidity and mortality remain undisputed [10,11], the impact of
pre-existing AF on operative outcomes in patients undergoing
CABG remains equivocal. A few cohort studies have recently
identiﬁed the association between preoperative AF and greater
morbidity and mortality in patients undergoing surgery for
ischemic heart disease [5,8,12–15], with recommendations to
consider concomitant AF ablation during the surgery [8,14].gy.
A. Saxena et al. / Journal of Cardiology 65 (2015) 224–229 225However, the current literature remains sparse and commonly
used risk calculators for cardiac surgery, such as the EuroSCORE,
are yet to recognize pre-op AF as a risk modiﬁer [16,17].
This study was designed to identify the potential impact of
pre-op AF on the early and late operative outcomes in a large
cohort of patients, from the Australasian Society of Cardiac and
Thoracic Surgeons (ASCTS) Cardiac Surgery Database, with
ischemic heart disease undergoing isolated CABG surgery.
Methods
The inclusion criterion for the study was patients undergoing
isolated CABG between June 1, 2001 and December 31, 2009, at
hospitals in Australia participating in the ASCTS Cardiac Surgery
Database. Patients having any other concomitant cardiac surgical
procedures, in particular, atrial arrhythmia surgery, were exclud-
ed. A detailed description of data collection and validation
methods has been previously provided [18,19].
Pre-op AF was deﬁned by evidence of a pre-op AF by clinical
documentation that required treatment. For the purpose of this
study, patients were separated into two groups based on the
presence of pre-op AF or not (no pre-op AF group). Preoperative
characteristics, early outcomes, and long-term survival were
compared between the two groups. Late mortality was deﬁned
as death from any cause that occurred at any time after hospital
discharge.
Fourteen early postoperative outcomes were analyzed. These
were as follows: (a) 30-day mortality, deﬁned as death within 30
days of operation; (b) permanent stroke, deﬁned as a new central
neurologic deﬁcit persisting for >72 h; (c) transient stroke, deﬁned
as a transient neurologic deﬁcit (transient ischemic attack or
reversible ischemic neurologic deﬁcit); (d) postoperative acute
myocardial infarction (AMI), deﬁned as at least two of the
following: enzyme level elevation, new cardiac wall motion
abnormalities, or new Q waves on serial electrocardiograms; (e)
new renal failure, deﬁned as at least two of the following: serum
creatinine increased to more than 200 mmol/L, doubling or greater
increase in creatinine vs. preoperative value, or new requirement
for dialysis or hemoﬁltration; (f) prolonged ventilation (>24 h); (g)
multisystem failure, deﬁned as concurrent failure of two or more of
the cardiac, respiratory, or renal systems for at least 48 h; (h)
septicemia, deﬁned as positive blood cultures supported by at least
two of the following indices of clinical infection: fever, elevated
granulocyte cell counts, elevated and increased C-reactive protein,
and elevated and increased erythrocyte sedimentation rate,
postoperatively; (i) gastrointestinal (GI) complications, deﬁned
as postoperative occurrence of any GI complication; (j) deep
sternal infection involving muscle and bone as demonstrated by
surgical exploration and one of the following: positive cultures or
treatment with antibiotics; (k) pneumonia diagnosed by one of the
following: positive cultures of sputum, blood, pleural ﬂuid,
empyema ﬂuid, transtracheal ﬂuid or transthoracic ﬂuid, consis-
tent with the diagnosis and clinical ﬁndings of pneumonia; (l) red
blood cell transfusion postoperatively; (m) return to the operating
theater for any cause; and (n) return to the operating theater for
bleeding.
To assess the impact of pre-op AF on each outcome, logistic
regression analysis was used to adjust for 21 preoperative patient
variables, with the outcome as the dependent variable. Long-term
survival status was obtained from the Australian National Death
Index. The closing date was March 18, 2010. A Kaplan–Meier
estimate of survival was obtained. Differences in long-term
survival were assessed by the log-rank test. The role of pre-op
AF in long-term survival was assessed by constructing a Cox
proportional hazards model using pre-op AF and other preopera-
tive patient characteristics as variables. Continuous variables arepresented as mean  one standard deviation. The independent
samples t-test was used to compare two groups of continuous
variables. The Fisher’s exact test or the Chi-square test was used to
compare groups of categoric variables. All calculated values of p were
two-sided, and p < 0.05 was considered signiﬁcant. Statistical
analysis was performed using SPSS1 for Windows version 17.0
(SPSS, Munich, Germany).
Results
CABG surgery was undertaken in 21,534 patients at 18
Australian institutions. Of these 1312 (6.1%) patients presented
with pre-op AF. Preoperative and demographic characteristics of
pre-op AF and no pre-op AF patients are provided in Table 1. There
were some differences in intraoperative variables between the two
groups. These are summarized in Table 2.
Overall 30-day mortality and in-hospital mortality were 1.6%
and 1.8%, respectively. The unadjusted 30-day mortality rate was
1.4% in patients without pre-op AF and 4.2% in patients with pre-op
AF. This difference was signiﬁcant on univariate analysis
(p < 0.001). The independent association of pre-op AF with other
postoperative outcomes is summarized in Table 3. The logistic
regression model predicting 30-day mortality is shown in Table 4.
This model has a Hosmer–Lemeshow x2 statistic of 5.26 (p = 0.73)
and demonstrates that pre-op AF was an independent predictor for
30-day mortality (p = 0.004). On univariate analysis, patients with
pre-op AF had a signiﬁcantly higher mean postoperative length of
stay (11.27  11.41 days vs. 8.49  8.93 days, p < 0.001) and
intensive care unit stay (61.77  99.49 h vs. 42.77  96.44 h,
p < 0.001) compared to patients who did not develop pre-op AF.
The mean follow-up period for this study was 37 (range, 0–106)
months. Long-term survival at 1, 3, 5, and 7 years postoperatively
was signiﬁcantly lower in patients who developed pre-op AF
compared to those who did not (97.1% vs. 91.2%, 94.3% vs. 86.5%,
89.7% vs. 77.7%, and 84.8% vs. 68.7%, p < 0.001). Fig. 1 shows
survival outcomes in patients with and without pre-op AF prior to
adjusting for confounding variables. After adjusting for differences
in patient variables, pre-op AF was independently associated with
reduced long-term survival (p < 0.001). A Cox regression model
predicting late mortality is summarized in Table 4.
Discussion
Whether pre-op AF is an independent risk factor for poorer
perioperative outcomes and late survival or simply a marker of a
more complex physiological milieu is controversial. Studies have
consistently shown that patients with pre-op AF are sicker and
have signiﬁcantly more comorbidities [7,9,12,14,20]. Consistent
with this, we found that patients with pre-op AF were older, had
more cardiovascular risk factors, more extensive coronary artery
disease, and presented more often in a critical perioperative state.
These factors undoubtedly contributed to the poorer outcomes
observed in patients with pre-op AF. Our large study demonstrat-
ed, however, that even after accounting for these factors, pre-op AF
was associated with poorer short-term and long-term outcomes.
The overall 30-day mortality in our study was 1.6%. This is lower
than that reported in many series and reﬂects the continuous
improvements in technical aspects of cardiothoracic surgery,
anesthesia, and perioperative care in the contemporary era [20–
23]. The 30-day mortality was 4.2% and 1.4% in patients with and
without pre-op AF, respectively. This was signiﬁcant on multivari-
ate analysis (p = 0.004). The association of pre-op AF with early
mortality has been previously described. Attaran et al. [20]
evaluated 1800 matched patients who underwent a spectrum of
cardiac surgery procedures and demonstrated that pre-op AF was
associated with a 51% increase in early mortality (7.4% vs. 4.9%,
Table 1
Preoperative characteristics and patient demographics, stratiﬁed by preoperative atrial ﬁbrillation (pre-op AF).
Preoperative variables No pre-op AF Pre-op AF p
Total number of patients (%) 20,222 1312 –
Age (mean  S.D.) 65.20  10.53 71.05  8.69 <0.001
Female (%) 4472 (22.1) 308 (23.5) 0.250
Chronic obstructive pulmonary disease (%) 2346 (11.6) 244 (18.6) <0.001
Diabetes mellitus (%) 6567 (32.5) 468 (35.7) 0.016
Hypercholesterolemia (%) 16,308 (80.6) 1001 (76.3) <0.001
Hypertension (%) 15,504 (76.7) 1075 (81.9) <0.001
Cerebrovascular disease (%) 2172 (10.7) 216 (16.5) <0.001
Peripheral vascular disease (%) 2430 (12.0) 237 (18.1) <0.001
Renal failure (%) 652 (3.2) 64 (4.9) 0.001
Previous cardiac surgery (%) 707 (3.5) 77 (5.9) <0.001
Recent myocardial infarction (<21 days) (%) 5049 (25.0) 430 (32.8) <0.001
History of congestive heart failure (%) 3016 (14.9) 390 (29.7) <0.001
Unstable angina (%) 1696 (8.4) 116 (8.8) 0.565
Left main stenosis >50% 5147 (25.5) 371 (28.3) 0.024
Left ventricular ejection fraction – – <0.001
Normal (ejection fraction >0.60) (%) 9564 (47.3) 402 (30.6) –
Mild (ejection fraction >0.45) (%) 6239 (30.9) 441 (33.6) –
Moderate (ejection fraction 0.30–0.45) (%) 3050 (15.1) 336 (25.6) –
Severe (ejection fraction <0.30) (%) 864 (4.3) 104 (7.9) –
Obesity (%) 6582 (32.5) 417 (31.8) 0.583
New York Heart Association classiﬁcation (%) – – <0.001
Class I (%) 7595 (37.6) 337 (25.7) –
Class II (%) 6720 (33.2) 385 (29.3) –
Class III (%) 3252 (16.1) 276 (21.0) –
Class IV (%) 1063 (5.3) 147 (11.2) –
Triple-vessel disease (%) 14,497 (71.7) 999 (76.1) <0.001
Critical preoperative state (%) 1403 (6.9) 160 (12.2) <0.001
Status – – <0.001
Elective (%) 11,717 (59.9) 669 (51.0) –
Emergency/salvage (%) 7637 (37.8) 571 (43.5) –
Urgent (%) 867 (4.3) 71 (5.4) –
EuroSCORE (additive) (mean  S.D.) 6.47  3.23 8.40  3.46 0.001
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portends a poor early outcome. Ngaage et al. [8] in an analysis of
7698 patients who underwent isolated CABG at the Mayo Clinic
showed no association between pre-op AF and early mortality
(1.6% vs. 1.9%, p = 0.79). Overall, a careful review of published
series suggests that pre-op AF is likely to be a risk factor for early
mortality and our results are consistent with this [5,14,15,20,24].
Further prospective studies, however, are necessary to explore this
association further.
Patients with pre-op AF had a higher incidence of some early
complications, but not all. Complications including new-onset
renal failure, transient stroke, and return to theater were more
likely to develop in patients with pre-op AF (all p < 0.05). Several
mechanisms have been proposed to explain the association
between pre-op AF and poorer early outcomes. It has been
suggested that reduced ventricular ﬁlling due to AF results in
hypoperfusion of end organs such as the brain and kidneys,
rendering patients susceptible to stroke and renal impairment
[9,20]. Fortunately our study suggests that cerebrovascular
sequelae in patients with pre-op AF are likely to be transient;Table 2
Intraoperative characteristics, stratiﬁed by preoperative atrial ﬁbrillation (pre-op AF).
Preoperative variables No pre-
Total number of patients (%) 20,2
Off-pump procedures (%) 1613 (
Number of distal anastomoses (mean  S.D.) 3.2
Cardiopulmonary bypass time (min) (mean  S.D.) 65.1
Aortic cross-clamp time (min) (mean  S.D.) 64.0
Internal mammary artery graft used (%) 19,100 (
Left internal mammary artery graft used (%) 18,889 (
Right internal mammary artery graft used (%) 2652 (
Radial artery graft used (%) 11,911 (there was no increase in the rate of permanent stroke observed in
this group of patients. Postprocedural length of stay and length of
ICU stay are surrogate markers for cost and resource utilization.
The mean length of ICU stay (61  99 h vs. 43  96 h, p < 0.001) and
postprocedural length of stay (11  11 days vs. 8  9 days, p < 0.001)
were signiﬁcantly higher in patients with pre-op AF. The overall cost
of hospitalization, therefore, is likely to be signiﬁcantly higher in this
group of patients. Unfortunately, to the best of our knowledge, there
is no cost analysis which has addressed this issue.
Our study showed that pre-op AF was an independent risk
factor for late mortality. Our ﬁndings agree with those of most
published series [7–9,15,20,25]. The cause for increased mortality
in patients with pre-op AF has been investigated and several
mechanisms have been proposed. Firstly, pre-op AF may predis-
pose patients to thromboembolic or hemorrhagic events [20].
Secondly, long-term AF may cause tachycardia-induced cardiomy-
opathy [26,27]. Finally, long-term AF may exacerbate congestive
heart failure [28]. Other large series have consistently demon-
strated that pre-op AF increases late mortality [8,9,15,20,24].
Banach et al. [15] in an analysis of 3000 patients who underwentop AF Pre-op AF p
22 1312 –
8.0) 103 (7.9) 0.911
  1.0 3.2  1.1 0.606
  34.4 63.8  33.0 0.006
  33.2 65.5  34.1 0.199
94.5) 1194 (91.0) <0.001
93.4) 1179 (90.0) <0.001
13.1) 133 (10.1) 0.004
58.9) 633 (48.2) <0.001
Table 3
Early outcomes, stratiﬁed by preoperative atrial ﬁbrillation (pre-op AF).
Outcome No pre-op AF Pre-op AF p Adjusted hazard ratio (95% CI)
Permanent stroke (%) 151 (0.7) 18 (1.4) 0.976 1.01 (0.56–1.82)
Transient stroke (%) 74 (0.4) 13 (1.0) 0.030 2.05 (1.07–3.92)
Postoperative myocardial infarction (%) 152 (0.8) 6 (0.5) 0.410 0.71 (0.31–1.62)
New renal failure (%) 687 (3.4) 92 (7.0) 0.046 1.30 (1.01–1.67)
Deep sternal wound infection (%) 142 (0.7) 16 (1.2) 0.146 1.51 (0.87–2.64)
Pneumonia (%) 891 (4.4) 64 (4.9) 0.767 0.96 (0.73–1.26)
Septicemia (%) 194 (1.0) 19 (1.4) 0.603 1.14 (0.69–1.89)
Multisystem failure (%) 150 (0.7) 21 (1.6) 0.644 1.13 (0.67–1.89)
Prolonged ventilation (%) 1679 (8.3) 192 (14.6) 0.063 1.20 (0.99–1.45)
Gastrointestinal complications (%) 218 (1.1) 24 (1.8) 0.769 1.08 (0.66–1.75)
Red blood cell transfusion (%) 7650 (37.8) 598 (45.6) 0.666 0.97 (0.85–1.11)
Return to theater (%) 961 (4.8) 108 (8.2) 0.002 1.44 (1.15–1.81)
Return to theater for bleeding (%) 472 (2.3) 37 (2.8) 0.801 1.05 (0.72–1.53)
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lower among patients who had pre-op AF (71% vs. 91%, p < 0.001).
These results were commensurate with those reported by Rogers
et al. [9] who also demonstrated a 20% survival difference in
survival among patients with and without pre-op AF [70% vs. 90%,
hazard ratio (HR), 1.49; 95% conﬁdence interval (CI), 1.06–2.08,
p = 0.020]. An important limitation of most studies, including the
current one, is the lack of information on the cause of late
mortality. Only all-cause late mortality was considered in the
majority of published series. Prospective studies with rigorous
follow-up are required to evaluate the cause for late mortality in
this group of patients.
The current study has several strengths. An important strength
is that this is a large, contemporary study from a validated, multi-
institutional database. Moreover, our study has important clinical
implications. It adds to the growing literature about the signiﬁcant
impact of pre-op AF on mortality and morbidity after cardiac
surgery. The results suggest that pre-op AF should be given special
attention as it carries a higher operative risk and worse prognosis
in patients undergoing CABG. This independent risk factor is not
currently incorporated in most cardiac surgery risk calculators, and
we hope that the results of this study will prompt a revision of
these algorithms, as was done by the US Society of Thoracic
Surgeons (STS), to include pre-op AF in the risk model (STS version
2.61) [21]. It should be noted, however, that the STS model does notTable 4
Multivariate analysis of 30-day mortality and late mortality.
Preoperative variables 30-Day
Hazard ratio (95% CI
Age (mean  S.D.) 1.05 (1.03–1.06) 
Preoperative atrial arrhythmia 1.63 (1.17–2.29) 
Current smoker 1.07 (0.70–1.53) 
Female 1.24 (0.95–1.61) 
Chronic obstructive pulmonary disease 1.03 (0.75–1.42) 
Diabetes mellitus 1.02 (0.78–1.30) 
Hypercholesterolemia 0.81 (0.61–1.06) 
Hypertension 1.23 (0.89–1.69) 
Cerebrovascular disease 0.83 (0.59–1.17) 
Peripheral vascular disease 1.34 (1.00–1.80) 
Renal failure 1.84 (1.22–2.77) 
Obesity 1.02 (0.78–1.34) 
Recent myocardial infarction (<21 days) 1.54 (1.17–2.03) 
History of congestive heart failure (%) 1.89 (1.43–2.49) 
Unstable angina (%) 1.58 (1.17–2.13) 
Left main stenosis >50% 1.30 (1.01–1.66) 
Left ventricular ejection fraction <0.45 1.94 (1.49–2.53) 
New York Heart Association classiﬁcation III or IV 1.43 (1.10–1.87) 
Triple-vessel disease 1.16 (0.85–1.57) 
Nonelective procedure 1.61 (1.19–2.18) 
Critical preoperative state 2.45 (1.81–3.30) stratify the risk by the type and duration of AF, and further studies
are required to investigate the speciﬁc impact of these variables.
Concomitant surgical intervention has been advocated by several
studies in patients with pre-op AF undergoing CABG [8,28]. In
theory, ablation of the arrhythmia in patients undergoing CABG
should improve the patient outcomes. A recent meta-analysis
concluded that there is an improvement in postoperative out-
comes in patients with valvular disease and AF who undergo a
concomitant ablation procedure [29]. While our ﬁndings support
that restoring sinus rhythm in patients with pre-op AF may be
warranted, further well-deﬁned, randomized controlled trials are
necessary to investigate the role of concomitant ablation in
patients undergoing CABG.
Our study, however, also has several limitations, the most
important of which is its retrospective nature. Our database did not
allow us to classify patients according to the current accepted
deﬁnitions of paroxysmal, persistent, and permanent AF. The
association observed between pre-op AF and late mortality also
does not necessarily imply causation. Although, cerebrovascular
accidents and myocardial infarction secondary to AF are well
recognized, our study does not provide autopsy results and only
all-cause mortality was considered. Our dataset lacks information
on drug medication at discharge and during follow-up. In
particular, knowledge about the administration of antiarrhythmic
medication and long-term use of anticoagulation therapy during mortality Late mortality
) p value Hazard ratio (95% CI) p value
<0.001 1.06 (1.06–1.07) <0.001
0.004 1.39 (1.20–1.61) <0.001
0.699 1.39 (1.19–1.58) <0.001
0.114 0.91 (0.82–1.02) 0.104
0.834 1.32 (1.18–1.49) <0.001
0.948 1.23 (1.12–1.36) <0.001
0.128 0.77 (0.68–0.86) <0.001
0.218 1.21 (1.06–1.37) 0.003
0.280 1.27 (1.13–1.43) <0.001
0.051 1.54 (1.38–1.72) <0.001
0.004 2.32 (1.95–2.76) <0.001
0.869 1.03 (0.93–1.15) 0.570
0.002 1.04 (0.92–1.17) 0.529
<0.001 1.50 (1.35–1.68) <0.001
0.003 0.98 (0.84–1.14) 0.798
0.041 1.14 (1.03–1.27) 0.014
<0.001 1.58 (1.42–1.75) <0.001
0.008 1.19 (1.07–1.32) 0.001
0.360 1.18 (1.04–1.33) 0.008
0.002 1.10 (0.98–1.23) 0.114
<0.001 1.52 (1.31–1.76) <0.001
Fig. 1. Nonrisk-adjusted overall survival in patients with and without preoperative
atrial ﬁbrillation (pre-op AF).
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Management of AF postcardiac surgery may also not be optimal.
There is now substantial evidence from randomized controlled
trials that rate control is as effective as rhythm control in managing
patients with AF [30]. A signiﬁcant proportion of patients with AF
after CABG, however, are managed with antiarrhythmics rather
than rate control medications and this may not represent the
optimal medical treatment given that antiarrhythmic drugs, in
particular, amiodarone, have signiﬁcant side effects [30,31]. The
association observed between pre-op AF and late mortality also
does not necessarily imply causation. Although, cerebrovascular
accidents and myocardial infarction secondary to AF are well
established, our study does not provide autopsy results and only
all-cause mortality was considered. Finally, we acknowledge a
limitation in our methodology. Although we attempted to adjust
for a variety of variables, we acknowledge that unmeasured factors
may have inﬂuenced outcomes. Nevertheless, we believe, that our
study demonstrates with sufﬁcient conviction that pre-op AF
portends poor early and late outcomes in patients undergoing
isolated CABG surgery.
In conclusion, our study suggests that pre-op AF is an
independent risk factor for poorer early and late outcomes after
isolated CABG surgery. The incidence of pre-op AF will increase
given that patients undergoing CABG surgery are getting older. It is
imperative, therefore, to be aware of the increased risk in these
patients. Pre-op AF should be evaluated as a potential risk factor in
future scoring systems. Nevertheless, studies are required to
ascertain the impact of the duration and type of AF on early and
late outcomes and the potential utility of concomitant surgical
ablation in improving outcomes.
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